Agenus (AGEN) Q2 2026 earnings summary

Executive summary

• Achieved net income of $38.6 million for the six months ended June 30, 2026, compared to a net loss of $53.3 million year-over-year, driven by a $40.4 million gain on the Zydus asset sale and increased non-cash royalty revenue from GSK vaccine sales.

• Strategic focus shifted to neoadjuvant BOT/BAL in MSS colon cancer, with the launch of the ROBBIN Phase 3 trial and discontinuation of financial support for the BATTMAN study.

• Advanced the Phase 3 ROBBIN trial of BOT + BAL in neoadjuvant MSS colon cancer, targeting high-risk Stage II and III patients, with initiation and first patient dosing expected in Q1 2027.

• Closed a private placement in July 2026, raising $85 million upfront, with potential for $255 million more upon warrant exercise.

• BOT + BAL access programs expanded internationally, generating $6.4 million in Q2 pre-commercial product revenue.

Financial highlights

• Total revenue for the six months ended June 30, 2026, was $68.3 million, up from $49.8 million year-over-year, primarily due to higher non-cash royalty revenue and pre-commercial product revenue.

• Q2 2026 total revenue was $34.5 million, up 34% year-over-year, with pre-commercial product revenue from BOT + BAL access programs reaching $6.4 million.

• Operating expenses decreased 47% to $41.9 million, reflecting lower R&D and G&A costs after the Zydus manufacturing sale and MiNK deconsolidation.

• Cash and cash equivalents rose to $18.7 million as of June 30, 2026, from $3.0 million at year-end 2025, excluding $7.6 million in escrow and $85 million from the subsequent private placement.

• Outstanding debt was $30.4 million, down from $45.5 million at year-end 2025.

Outlook and guidance

• Current cash, cash equivalents, and private placement proceeds are expected to fund operations and the ROBBIN trial into Q3 2027, with full warrant exercise potentially extending runway through 2031.

• Additional capital will be required to advance registration and commercialization of BOT/BAL and achieve profitability.

• Near-term milestones include manuscripts from NEST and UNICORN studies in H2 2026 and ROBBIN trial initiation in Q1 2027.

• Actively pursuing further financing, strategic partnerships, and cost management measures.